Robotic Exoskeleton Company, Ekso Bionics Announces Completion of Private Placement Offering

Ekso Bionics Holdings, Inc., a robotic exoskeleton company, today announced that it completed its private placement offering as part of its January 15, 2014 announced alternative public offering ("APO"). Shares of the Company's common stock are currently quoted on the OTC Markets under the symbol "EKSO."

"We are pleased at the interest we have received from investors in this APO financing." said Nathan Harding, the Company's Chief Executive Officer. "We originally targeted a financing in the range of $12-20 million. Given the level of interest from qualified individual and institutional investors we increased our offering to just over $30 million. We now have a large and committed investor base and will continue to define the industry for exoskeletons and develop break-through technology."


Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military, industrial, and consumer markets. Exoskeletons are ready-to-wear, battery-powered robots that are strapped over the user's clothing, enabling individuals to achieve mobility, strength, and endurance not otherwise possible.

Ekso Bionics' lead product, Ekso™, is a wearable bionics suit that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury and other neurological conditions affecting gait.

Steven Sherman, the Company's Chairman added, "I am very proud of the initial success of the Ekso in rehabilitation centers worldwide, as well as the recent surge of media awareness that explores the range of possibilities for bionic robots. We see a future with wearable robots that enable people to walk again, as well as enhance their daily lives."

With this closing, the Company has raised a total in gross proceeds of $30,300,000 through the sale of 30,300,000 units at a price of $1.00 per share. Each unit includes one share of the Company's common stock and a warrant to purchase one share of the Company's common stock at an exercise price of $2.00 per share for a five-year period. After giving effect to the final closing, there are approximately 78,500,000 shares of Company common stock outstanding.

Gottbetter Capital Markets, LLC was the exclusive placement agent for the offering, and EDI Financial, Inc. was a sub-agent. Lead investors included Opaleye L.P. and Montrose Capital Partners. Further details on the APO financing can be found in the Company's 8-K filing on January 23, 2014.

http://www.eksobionics.com

Featured Product

BitFlow Introduces 6th Generation Camera Link Frame Grabber: The Axion

BitFlow Introduces 6th Generation Camera Link Frame Grabber: The Axion

BitFlow has offered a Camera Link frame grabbers for almost 15 years. This latest offering, our 6th generation combines the power of CoaXPress with the requirements of Camera Link 2.0. Enabling a single or two camera system to operate at up to 850 MB/S per camera, the Axion-CL family is the best choice for CL frame grabber. Like the Cyton-CXP frame grabber, the Axion-CL leverages features such as the new StreamSync system, a highly optimized DMA engine, and expanded I/O capabilities that provide unprecedented flexibility in routing. There are two options available; Axion 1xE & Axion 2xE. The Axion 1xE is compatible with one base, medium, full or 80-bit camera offering PoCL, Power over Camera Link, on both connectors. The Axion 2xE is compatible with two base, medium, full or 80-bit cameras offering PoCL on both connectors for both cameras. The Axion-CL is a culmination of the continuous improvements and updates BitFlow has made to Camera Link frame grabbers.